Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica
; 109(1): 343-350, 2024 Jan 01.
Article
en En
| MEDLINE
| ID: mdl-37470152
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfoma de Células del Manto
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Haematologica
Año:
2024
Tipo del documento:
Article